| Literature DB >> 28699299 |
Stephanie O M Dyke1, Bartha M Knoppers1, Ada Hamosh2, Helen V Firth3, Matthew Hurles3, Michael Brudno4,5, Kym M Boycott6, Anthony A Philippakis7, Heidi L Rehm7,8.
Abstract
The Matchmaker Exchange (MME) connects rare disease clinicians and researchers to facilitate the sharing of data from undiagnosed patients for the purpose of novel gene discovery. Such sharing raises the odds that two or more similar patients with candidate genes in common may be found, thereby allowing their condition to be more readily studied and understood. Consent considerations for data sharing in MME included both the ethical and legal differences between clinical and research settings and the level of privacy risk involved in sharing varying amounts of rare disease patient data to enable patient matches. In this commentary, we discuss these consent considerations and the resulting MME Consent Policy as they may be relevant to other international data sharing initiatives.Entities:
Keywords: consent; data access; data sharing; personalized medicine; precision medicine; privacy
Mesh:
Year: 2017 PMID: 28699299 PMCID: PMC5669800 DOI: 10.1002/humu.23278
Source DB: PubMed Journal: Hum Mutat ISSN: 1059-7794 Impact factor: 4.878